Recorded by Cello Health, now part of Lumanity

Episode 1

In this first episode, Joel sits down with Michael Parisi, CEO of Guidemark, and Michael Rice, Vice President, Head of Advanced Therapeutics, to explore:

  • How uncovering non-small-cell lung cancer (NSCLC) and spinal muscular atrophy (SMA) genetics led to record-speed options for patients with rare subtypes
  • How the patient advocacy groups enabled translation
  • How the provider infrastructure is evolving to meet the need for genetic precision
  • What pharma brought upon entering and how the lessons shape their and field’s outlook
  • What’s next for rare disease drug development

Podcast Series: Therapeutic Science and Strategy

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content.